NASDAQ
28.01.26 | 22:00
11,850 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Cullinan Therapeutics: Wichtige Studiendaten zu Autoimmun- und Krebstherapien für 2026 geplant | 3 | Investing.com Deutsch | ||
| 08.01. | Cullinan Therapeutics plans data readouts for key autoimmune programs | 2 | Investing.com | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.01. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | 602 | GlobeNewswire (Europe) | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| 08.01. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data | 5 | Investing.com | ||
| 08.12.25 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting | 15 | GlobeNewswire (USA) | ||
| 08.12.25 | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Cullinan Therapeutics Announces Fast Track Designation For CLN-049 | 2 | RTTNews | ||
| 01.12.25 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 227 | GlobeNewswire (Europe) | Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01... ► Artikel lesen | |
| 26.11.25 | Cullinan Oncology stock price target raised to $36 at Jones Trading | 2 | Investing.com | ||
| 25.11.25 | Vielversprechende AML-Daten: BTIG erhöht Kursziel für Cullinan Oncology auf 38 US-Dollar | 12 | Investing.com Deutsch | ||
| 25.11.25 | Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data | 2 | Investing.com | ||
| 21.11.25 | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | H.C. Wainwright raises Cullinan Oncology stock price target on NDA progress | 4 | Investing.com | ||
| 21.11.25 | Fortschritte bei Zipalertinib-Zulassung: H.C. Wainwright hebt Kursziel für Cullinan Oncology an | 13 | Investing.com Deutsch | ||
| 20.11.25 | Cullinan Therapeutics rises on rolling submission for zipalertinib | 1 | Seeking Alpha | ||
| 06.11.25 | Cullinan Therapeutics GAAP EPS of -$0.77 | 3 | Seeking Alpha | ||
| 06.11.25 | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.11.25 | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,608 | +0,65 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,585 | -0,63 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| IMMUNITYBIO | 5,242 | +1,71 % | ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run | ||
| VOYAGER THERAPEUTICS | 3,384 | +1,93 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CAPRICOR | 17,740 | -1,77 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data |
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,600 | +4,83 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,120 | +1,48 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,585 | 0,00 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| DBV TECHNOLOGIES | 4,020 | -2,43 % | DBV Technologies S.A.: DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing | Châtillon, France, January 16, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 65,50 | -0,76 % | Palvella Therapeutics Inc.: Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved ... | Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 12,600 | -0,79 % | KalVista Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MARKER THERAPEUTICS | 1,350 | 0,00 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,800 | -1,69 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 7,150 | +5,15 % | H.C. Wainwright bestätigt Kaufempfehlung für Aligos Therapeutics nach Fortschritten bei Pevifoscorvir | ||
| QUANTUM-SI | 1,200 | 0,00 % | Quantum-Si Inc - 8-K, Current Report |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 11,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.